Kalpalatha Guntupalli

Kalpalatha Guntupalli

Auto-generated profile, based on publicly available information

Kalpalatha Guntupalli

From Baylor College of Medicine, Houston, Texas

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Chest
Verified
Journal Article
Closed access
PDF file
KGKalpalatha K. Guntupalli
Kalpalatha K. Guntupalli
NHNicole Hall
Nicole Hall
DKDilip R. Karnad
Dilip R. Karnad
VBVenkata Bandi
Venkata Bandi
MBMichael Belfort
Michael Belfort

30 June 2010 in Critical Care
Verified
Journal Article
Open access
PDF file
PMPeter E Morris
Peter E Morris
JPJohn T Promes
John T Promes
KGKalpalatha K Guntupalli
Kalpalatha K Guntupalli
PWPatrick E Wright
Patrick E Wright
MAMurray M Arons
Murray M Arons
Introduction: Hospitalized patients are often unable to ingest or tolerate oral antipyretics and recently an aqueous formulation of intravenous (IV) ibuprofen was approved by the US-FDA for the reduction of fever in adults. Methods: We evaluated IV ibuprofen to reduce fever exceeding 101.0°F, measured as the percentage of subjects achieving a temperature <101.0°F at four hours after a single dose of IV ibuprofen vs. placebo. Secondary evaluations included the effect on temperature at 24 hours. Nine sites randomized patients to receive either a placebo or IV ibuprofen (100, 200, or 400 mg), and patients were given four hours for six doses. Subjects were excluded for platelet count 3.0 mg/dL. Results: At entry, there were no significant baseline differences between the IV ibuprofen group and placebo, n = 120. At four hours, the number (percentage) with T<101.0°F was: Placebo n = 9/28 (32%); 100 mg IV ibuprofen n = 19/31 (61%), P = 0.0264; 200 mg IV ibuprofen n = 21/30 (70%) P = 0.0043; 400 mg IV ibuprofen n = 24/31 (77%) P = 0.0005. A total of 53/120 patients (44%) were prospectively defined as critically ill at baseline and similar temperature reductions were observed in this subgroup. There were no statistically significant differences between treatment groups or when compared to placebo in transfusion, bleeding, renal failure or mortality. Conclusions: All doses of IV ibuprofen tested reduced fever at four hours and throughout the first 24 hours of dosing. The 400 mg dose was effective in lowering temperature to normal and maintaining this over the first 24 hours of dosing. IV ibuprofen was effective in reducing fevers in critically ill and non-critically ill groups. Following 24 hours of administration of IV ibuprofen, no clinically significant differences in any safety parameter including renal function or bleeding occurred through the 28-day follow-up period. Trial registrations: Clinicaltrials.gov registration number: NCT01131000.

1 November 2015 in Chest
Verified
Journal Article
Closed access
PDF file
KGKalpalatha K. Guntupalli
Kalpalatha K. Guntupalli
DKDilip R. Karnad
Dilip R. Karnad
VBVenkata Bandi
Venkata Bandi
NHNicole Hall
Nicole Hall
MBMichael Belfort
Michael Belfort

1 September 2018 in Sleep Medicine Clinics
Verified
Journal Article
Closed access
LALakshmy Ayyar
Lakshmy Ayyar
FSFidaa Shaib
Fidaa Shaib
KGKalpalatha Guntupalli
Kalpalatha Guntupalli

7 July 2020 in Indian Journal of Respiratory Care
Verified
Journal Article
Closed access
DNDharani Narendra
Dharani Narendra
PPPurvesh Patel
Purvesh Patel
ARAniket Shitalkumar Rali
Aniket Shitalkumar Rali
TGTaylor Garies
Taylor Garies
KGKalpalatha Guntupalli
Kalpalatha Guntupalli

2 March 2022 in Case Reports in Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
AAArchana Ayyar
Archana Ayyar
RSRachel D. Seaman
Rachel D. Seaman
KGKalpalatha Guntupalli
Kalpalatha Guntupalli
MTMary C. Tolcher
Mary C. Tolcher
Background. COPA syndrome is a rare autoimmune disease, demonstrating an autosomal dominant inheritance pattern with variable penetration that occurs more frequently in females than males. This disease manifests in childhood as pulmonary hemorrhage, arthritis, and renal disease. Case. We present a case of obstetric management of a 20-year-old nulligravida patient with a diagnosis of COPA syndrome. Her case was further complicated by multiple antepartum admissions for hypoxemia and a complex psychosocial history of substance use. On her first antepartum admission, rheumatology recommended management with hydroxychloroquine, inhaled corticosteroids (budesonide), and bronchodilators (albuterol inhaler) as needed. On admission for induction of labor, she was again noted to have oxygen desaturations. A chronic thrombus was noted on computed tomography (CT), and a multidisciplinary team was recommended against Valsalva. Thus, she had a primary cesarean delivery. Her postpartum course was only remarkable for improved oxygenation status. Conclusion. Management of COPA syndrome should be performed by a multidisciplinary team including maternal-fetal medicine, rheumatology, and pulmonology specialists. Traditionally, COPA syndrome is treated with immunomodulator therapy often used to treat autoimmune syndromes. However, many of these medications are not well studied or contraindicated in pregnancy. Preconception counseling is recommended both to ensure pregnancy safe medications being prescribed and to provide information on the genetic inheritance of this disease. At time of entry to care, patients should have a baseline work-up including a radiographic imaging, complete blood count, complete metabolic panel, lactate dehydrogenase, and a 24-hour urine protein collection for baseline. Although thought to be rare, COPA syndrome has an autosomal dominance pattern of inheritance with variable penetrance that is more common in females. Thus, incidence of COPA syndrome in pregnancy will likely increase in the future. Further case studies are warranted to optimize management of patients with COPA syndrome in pregnancy.